Utilities for advanced basal cell carcinoma

Journal of Medical Economics

Volumn 16, Issue 6, 2013, Pages 777-783

  Shingler, S L ^a   Garside, J ^b   Samanta, K ^c   Lear, J T ^d   Keohane, S ^e   Lloyd, A J ^a  

^a ICON PLC   (United Kingdom)

^b Roche Products Pty Ltd   (Australia)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^e ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Carcinoma, basal cell (advanced); Quality of life; Time trade off; Utility

Indexed keywords

ADVANCED CANCER; ARTICLE; BASAL CELL CARCINOMA; HEALTH STATUS; HUMAN; METHODOLOGY; QUALITY OF LIFE; SCORING SYSTEM; SEMI STRUCTURED INTERVIEW; TIME TRADE OFF METHODOLOGY; VISUAL ANALOG SCALE;

ADULT; ATTITUDE TO HEALTH; CARCINOMA, BASAL CELL; FEMALE; GREAT BRITAIN; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; QUALITATIVE RESEARCH; QUALITY OF LIFE; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84878913709     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.800822     Document Type: Article

References (21)

1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of non-melanoma skin cancer. Br J Dermatol 2012;166:1069-80
2. Kassi M, Kasi P, Afghan AK, et al. The role of fine-needle aspiration cytology in the diagnosis of basal cell carcinoma. ISRN Dermatology 2012;March:1-2. doi:10.5402/2012/132196
3. Rubin AI, Chen E, Ratnder D. Basal cell carcinoma. N Engl J Med 2005; 353:2262-9
4. Schwipper V. Invasive basal cell carcinoma of the head and neck (Basalioma Terebrans). Facial Plast Surg 2011;27:258-65
5. Lear J. Oral hedgehog-pathway inhibitors for basal-cell carcinoma. N Eng J Med 2012;366:2225-6
6. Madan V, Lear J, Szeimies RM. Non-melanoma skin cancer. Lancet 2010;375:673-85
7. Von Hoff D, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72
8. Ting PT, Kasper R and Arlette AP. Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg, 2005; 9:10-15.
9. National Institute for Health & Clinical Excellence (NICE). Guide to the methods of technology appraisal. London, UK: NICE, 2008. http://www.nice.org.uk/niceMedia/pdf/TAP-Methods.pdf. Accessed 12 November 2012
10. Shah K, Lloyd AJ, Oppe M, et al. One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands. Eur J Health Econ forthcoming; accepted article
11. Behmand R, Guyron B. Resection of bilateral orbital and cranial base basal cell carcinoma with preservation of vision. Ann Plast Surg 1996;36:637-40
12. Lear W, Akeroyd JE, Mittmann N. Measurement of utility in nonmelanoma skin cancer. J Cutan Med Surg 2008;12:102-6
13. Takemoto S, Fukamizu H, Yamanaka K, et al. Giant basal cell carcinoma: improvement in the quality of life after extensive resection. Scand J Plast Reconstr Surg Hand Surg 2003;37:181-5
14. Office for National Statistics. Office for National Statistics, 2001. Census 2001. http://www.ons.gov.uk/census/index.html. Accessed 12 November 2012
15. Swinburn P, Lloyd A, Nathan P, et al. Elicitation of health state utilities in metastatic renal cell carcinoma. Curr Med Res Opin 2010;26:1091-6
16. Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer 2006;95:683-90
17. Kind P, Dolan P, Gudex C, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736-41
18. Chen S, Bayoumi A, Soon S, et al. A catalogue of dermatology utilities: a measure of the burden of skin diseases. Soc Invest Dermatol Symp Proc 2004;9:160-8
19. Swinburn P, Lloyd A, Nathan P, et al. Elicitation of health state utilities in metastatic renal cell carcinoma. Curr Med Res Opin 2010;26:1091-6
20. Shingler S, Swinburn P, Lloyd AJ, et al. Elicitation of health state utilities in soft tissue sarcoma. Quality Life Res 2012; DOI 10.1007/s11136-012-0301-9.
21. Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer 2006;95:683-90